Simon Amy sold $13K of BEAM

Simon Amy (Chief Medical Officer) sold 373 shares of Beam Therapeutics Inc. (BEAM) at $34.73 on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Simon Amy
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BEAM
Neutral
high confidence
Mentioned
$BEAM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; it does not include new clinical, regulatory, or financial guidance.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure typically reduces interpretive weight versus unscheduled selling.

03

What to watch

The article provides no information on whether the sale was part of a broader pattern, nor any change in company outlook; without that, the signal quality is low.

Relevance 2/10Novelty 3/10Timing: filed July 2, transaction dated June 30

Background

This is an SEC Form 4 insider transaction disclosure for Beam Therapeutics, reported via EDGAR.

Company-level read

Ticker impact

$BEAMNeutralHigh confidence
Context

Beam Therapeutics disclosed a Form 4 showing CMO Simon Amy sold 373 shares on June 30 under a 10b5-1 plan.

Expected impact

Likely negligible near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes disclosed.

Market effects

No clear read-through to biotech sector fundamentals from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal risk management or diversification needs, which some traders may still fade.

Key entities

  • Beam Therapeutics Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Simon Amy

    Chief Medical Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.